Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
  • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
  • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P39/00—General protective or antinoxious agents
  • A61P39/06—Free radical scavengers or antioxidants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• composition for epigallocatechin gallate Composition for epigallocatechin gallate
• the present invention relates to a composition in the form of a powder and //ocr, granules, which contain as principal components (-)-epigallocatechin gallate (hereinafter: EGCG), together with a polysaccharide.
• EGCG principal components-epigallocatechin gallate
• EGCG is the most interesting compound among group of polyphenols contained in the leaves of the green tea plant Camellia sinensis because it exhibits a strong antioxidant effect. Furthermore, it has been demonstrated that EGCG has an antimutagenic effect, an antibacterial effect and also a beneficial effect on cholesterol level in blood. EGCG may be obtained by procedures described in, e.g., European patent application no.l 077 211 A2. EGCG is normally produced in crystalline powder form that has a very poor flowability. The poor powder flow renders the crystalline powder difficult for use in tablet formulation and other applications that require the powder to be free flowing.
• composition containing EGCG together with polysaccharides may be obtained in the form of a powder or of granules with improved flowability.
• the present invention relates to a composition in the form of a powder or granules comprising:
• the present invention relates to a method of producing the composition of the present invention.
• the invention is concerned with the use of polysaccharides, particularly pectin, for improving the flowability of EGCG powder.
• polysaccharides for use in the present invention are pectin, alginates, starch, cellulose derivatives such as hydroxypropyl methyl cellulose and carboxymethyl cellulose, carrageenan, agar, gum arabic, guar gum, xanthan gum and mixtures thereof.
• the preferred polysaccharide is pectin or alginate, most preferred is pectin.
• Pectin is a polysaccharide and described for example in the book entitled Industrial Gums, third edition, Academic Press, Inc., 1993, pages 257ff.
• Commercial pectins are generally produced from either citrus peel or apple pomace. Other possible sources are sugarbeet, sunflower and mango.
• Preferred pectins to be used within the scope of the present invention are citrus pectins, which generally have lighter color than apple pectins and, thus, do not impart significant color to the granule product.
• the polysaccharide is preferably used in quantities within the range of about 0.1 % to about 5 % by weight, based on the total weight of the composition. If pectin is used as the polysaccharide, it is preferably used in quantities of about 0.1 % to about 1 % by weight, based on the total weight of the composition. If alginate is used as the polysaccharide, it is preferably used in quantities of about 0.1 % to about 1 % by weight, based on the total weight of the composition. If starch is used as the polysaccharide, it is preferably used in quantities of about 0.1 % to about 5 % by weight, based on the total weight of the composition.
• composition of this invention may be produced by any method known per se for the production of powders or granules. Preferred are fluidized-bed granulation, high-shear granulation, extrusion, spray-drying and wet granulation.
• composition of the present invention by spray-drying it is convenient to prepare an aqueous slurry of all the components.
• the slurry has preferably a solid content of about 10 to 70% by weight, and preferably about 25 to 50% by weight.
• the slurry is then spray-dried in a manner known per se.
• the composition of the present invention by fluidized-bed granulation it is convenient to use a known fluidized-bed granulating apparatus which comprises a fluidized-bed drying device fitted with spray means.
• the EGCG forms the fluidized bed, the fluidized bed being fluidized by air or an inert gas, e.g. nitrogen.
• the polysaccharide or polysaccharides are dissolved in an appropriate amount of water and sprayed in the form of an atomized mist onto the fluidized particles in such a manner that the granulating and drying operations is accomplished in a single step.
• the polysaccharide or polysaccharides are mixed with EGCG and the fluidized bed being fluidized by air or an inert gas, e.g. nitrogen.
• An appropriate amount of water is sprayed in the form of an atomized mist onto the fluidized particles in such a manner that the granulating and drying operations is accomplished in a single step.
• the granulating process is continued until the desired-granule or powder is obtained.
• the granules may be sieved to fractionate the granules as to size. While the particle size is not narrowly critical to the invention it is, for practical purposes, preferably within 50 and 2000 micron, more preferably between 100 and 1000 microns.
• composition thus obtained may be further processed depending on the intended use of the EGCG or desired applications.
• the composition may be compressed into tablets with conventional tabletting methods and machinery.
• the powder or the granules may further be mixed with a lubricant or a mixture of lubricants and then compressed into tablets.
• additional lubricant it is preferably selected from the group of stearic acid or the magnesium or calcium salt thereof, or glyceryl behenate 45 (Compritol 888 ATO), preferably in an amount of about 0.5 to 4% by weight, calculated to the total weight of the composition.
• the composition ma be mixed with excipients. Examples for excipients are dextrinized sucrose (Di Pac sugar), microcrystalline cellulose or starch.
• EGCG powder as obtained by the procedures disclosed in EP 1 077 211 A2 may be used.
• a pectin solution is prepared by dissolving 27.3 g of pectin (Pectin USP, 8.4% moisture content, Danisco Ingredients, Denmark) in 1000 g of water.
• EGCG powder is placed in a Glatt Fluidized-Bed granulator (Model Uniglatt, Glatt GmbH, Germany) and sprayed with a fine mist of pectin solution.
• the granulation conditions are suitably as follows:
• the granules leaving the apparatus will have a moisture content of about 0.2 % by weight, based on the granule weight.
• a pectin solution was prepared by dissolving 5.82 g of pectin (Pectin USP/100, 8.96% moisture content, CP Kelco, Denmark) in 174.2 g of water.
• EGCG powder was placed in a Glatt Fluidized-Bed granulator (Model Uniglatt, Glatt GmbH, Germany) and sprayed with a fine mist of pectin solution.
• the granulation conditions were suitably as follows:
• the granule was dried for about 5 minutes to a moisture content of about 0.2 % by weight, based on the granule weight.
• Sieve analysis gave the following particle size distribution.
• Granulated EGCG was compared with EGCG powder (the starting material for granulation) for powder flowability using the Agway test.
• flowability is determined by placing 100 gram of the granules in a glass funnel with a 11-mm opening, which is sealed temporarily. The measurement is started by releasing the seal. Flowability is determined as the time for the entire powder to flow through the funnel in seconds per 100 g of granule.
• the time for a 100-g sample of the product obtained flowing through an 11 mm opening Agway funnel was 9.2 seconds.
• EGCG powder did not flow whereas granulated EGCG showed an acceptable flowability for use in tabletting and improved handling properties in various food and beverage applications.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• General Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Epidemiology (AREA)
• Inorganic Chemistry (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Diabetes (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Biochemistry (AREA)
• Toxicology (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Jellies, Jams, And Syrups (AREA)
• Fertilizers (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)

Priority Applications (9)

Applications Claiming Priority (2)

Publications (1)

Family

ID=8178165

Family Applications (1)

Country Status (13)

Cited By (3)

Families Citing this family (4)

Citations (12)

Family Cites Families (22)

• 2002
  • 2002-07-22 DE DE60225560T patent/DE60225560T2/de not_active Revoked
  • 2002-07-22 CA CA002450772A patent/CA2450772C/en not_active Expired - Fee Related
  • 2002-07-22 KR KR1020047001329A patent/KR100611855B1/ko not_active Expired - Fee Related
  • 2002-07-22 ES ES02762383T patent/ES2301670T3/es not_active Expired - Lifetime
  • 2002-07-22 CN CNA2007100964346A patent/CN101028253A/zh active Pending
  • 2002-07-22 JP JP2003516569A patent/JP2005501833A/ja active Pending
  • 2002-07-22 CN CNB028097823A patent/CN1325049C/zh not_active Expired - Fee Related
  • 2002-07-22 EP EP02762383A patent/EP1411986B1/en not_active Revoked
  • 2002-07-22 BR BR0209864-4A patent/BR0209864A/pt not_active Application Discontinuation
  • 2002-07-22 US US10/485,248 patent/US20040198673A1/en not_active Abandoned
  • 2002-07-22 MX MXPA04000618A patent/MXPA04000618A/es active IP Right Grant
  • 2002-07-22 AU AU2002327893A patent/AU2002327893B8/en not_active Ceased
  • 2002-07-22 AT AT02762383T patent/ATE388723T1/de not_active IP Right Cessation
  • 2002-07-22 WO PCT/EP2002/008127 patent/WO2003011339A1/en not_active Ceased

Patent Citations (12)

Non-Patent Citations (6)

Also Published As

Similar Documents

Legal Events